208 related articles for article (PubMed ID: 36324030)
1. Protein Phosphatase 2a Inhibits Gastric Cancer Cell Glycolysis by Reducing MYC Signaling.
Cai Z; Zhang W; Zhou R; Wang Y; Feng Y
Cell Biochem Biophys; 2023 Mar; 81(1):59-68. PubMed ID: 36324030
[TBL] [Abstract][Full Text] [Related]
2. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
[TBL] [Abstract][Full Text] [Related]
3. HMGA1 promoting gastric cancer oncogenic and glycolytic phenotypes by regulating c-myc expression.
Cao XP; Cao Y; Zhao H; Yin J; Hou P
Biochem Biophys Res Commun; 2019 Aug; 516(2):457-465. PubMed ID: 31229266
[TBL] [Abstract][Full Text] [Related]
4. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
5. CIP2A inhibits PP2A in human malignancies.
Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
[TBL] [Abstract][Full Text] [Related]
6. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
7. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
[TBL] [Abstract][Full Text] [Related]
8. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC
Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701
[TBL] [Abstract][Full Text] [Related]
9. CD73 is a hypoxia-responsive gene and promotes the Warburg effect of human gastric cancer cells dependent on its enzyme activity.
Cao X; Zhu Z; Cao Y; Hu J; Min M
J Cancer; 2021; 12(21):6372-6382. PubMed ID: 34659527
[No Abstract] [Full Text] [Related]
10. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Kim MO; Choe MH; Yoon YN; Ahn J; Yoo M; Jung KY; An S; Hwang SG; Oh JS; Kim JS
Biochem Pharmacol; 2017 Nov; 144():78-89. PubMed ID: 28813646
[TBL] [Abstract][Full Text] [Related]
11. Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer.
Kauko O; Westermarck J
Int J Biochem Cell Biol; 2018 Mar; 96():157-164. PubMed ID: 29355757
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of ZNF479 inhibits proliferation and glycolysis of gastric cancer cells through regulating β-catenin/c-Myc signaling pathway.
Jin XS; Ji TT; Shi ZC; Zhang QQ; Ye FP; Yu WL; Li RZ
Kaohsiung J Med Sci; 2021 Sep; 37(9):759-767. PubMed ID: 34042257
[TBL] [Abstract][Full Text] [Related]
13. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.
Yang JY; Huo YM; Yang MW; Shen Y; Liu DJ; Fu XL; Tao LY; He RZ; Zhang JF; Hua R; Jiang SH; Sun YW; Liu W
Mol Oncol; 2021 Nov; 15(11):3076-3090. PubMed ID: 33932092
[TBL] [Abstract][Full Text] [Related]
14. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
[TBL] [Abstract][Full Text] [Related]
16. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
Fujiki H; Sueoka E; Watanabe T; Suganuma M
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
[TBL] [Abstract][Full Text] [Related]
17. Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis.
Zhang Y; Huang P; Liu X; Xiang Y; Zhang T; Wu Y; Xu J; Sun Z; Zhen W; Zhang L; Si Y; Liu Y
J Pharmacol Sci; 2018 Jul; 137(3):305-312. PubMed ID: 30119963
[TBL] [Abstract][Full Text] [Related]
18. Type Iγ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer.
Peng W; Huang W; Ge X; Xue L; Zhao W; Xue J
EBioMedicine; 2019 Jun; 44():375-386. PubMed ID: 31105034
[TBL] [Abstract][Full Text] [Related]
19. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
20. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
Cristóbal I; González-Alonso P; Daoud L; Solano E; Torrejón B; Manso R; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mar Drugs; 2015 May; 13(6):3276-86. PubMed ID: 26023836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
